#EULAR2023 #POS1156 Previous case series reported ~9% de novo nephritis in #SLE pts treated with belimumab for non-renal lupus. Post-hoc analysis of 5 BEL Non-LN RCTs showed 8% had de novo LN. Risk increased in Asians but lowered with low dose BEL or s/c form @RheumNow https://t.co/GqAr3tppWh